CEO and Consultant
Enlightenment Bioconsult, LLC
Dr. Pezalla is respected leader in health insurance, health policy, and technology assessment, focusing on pharmaceuticals, devices and diagnostics. He consults with manufacturers on a range of compensation and payer issues including health technology assessment, value development and payer strategy.
Dr. Pezalla is CEO of Enlightenment Bioconsult and the former Vice President for Pharmaceutical Policy and Strategy in the Office of the Chief Medical Officer at Aetna. In this position Dr. Pezalla developed and coordinated strategy for pharmaceutical evaluation and coverage across both the medical and pharmacy benefit, created Aetna’s framework for innovative contracts, and developed Aetna’s public policy positions on drug and device coverage.
Dr. Pezalla is a member of the MIT NEWDIGS project on Adaptive Biomedical Innovation and has been a Scholar-in-Residence at the Duke Margolis Center for Health Policy. He is a former member of the Board of the Pharmacy Quality Alliance and the Connecticut Biosciences Innovation Fund. Dr. Pezalla is a current member of the Advisory Boards of Naia Pharmaceuticals, Temple Therapeutics and Verastem.
Prior to joining the Office of the Chief Medical Officer Dr. Pezalla was Chief Medical Officer and head of clinical activities for Aetna Pharmacy Management. Before joining Aetna he was VP for Clinical Services for Prescription Solutions, precursor to OptumRx, the PBM arm of United Health Group where he lead the development of the first Medicare Part D plan, the most successful product launch in the history of PacifiCare.
Tuesday, March 26
10:00 AM – 11:15 AM